GSK 070

Drug Profile

GSK 070

Alternative Names: GSK 070

Latest Information Update: 07 Jul 2016

Price : $50

At a glance

  • Originator Anacor Pharmaceuticals
  • Developer Anacor Pharmaceuticals; GlaxoSmithKline; Global Alliance for TB Drug Development
  • Class Antituberculars
  • Mechanism of Action Leucyl-tRNA synthetase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Tuberculosis

Most Recent Events

  • 24 Jun 2016 Anacor Pharmaceuticals has been acquired by Pfizer
  • 09 Apr 2016 Clinical trials for Tuberculosis (PO) in United Kingdom
  • 09 Apr 2016 Preclinical development for Tuberculosis (PO) in United Kingdom before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top